NCT02602990View on ClinicalTrials.gov

Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent

CompletedOBSERVATIONAL

Enrollment

50

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions

Cerebral Arteriovenous Malformations

Interventions

DEVICE

SQUID™

Trial Locations (6)

2650

UZ Antwerpen, Edegem

3000

UZ Leuven, Leuven

3600

Ziekenhuis Oost Limburg (ZOL), Genk

8500

AZ Groeninge, Kortrijk

9000

AZ Sint-Lucas, Ghent

45131

Alfried Krupp Krankenhaus, Essen

Sponsors

Lead Sponsor

Collaborators (1)

Archer Research

All Listed Sponsors

collaborator

Archer Research

INDUSTRY

lead

Emboflu

INDUSTRY

NCT02602990 - Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent | Biotech Hunter | Biotech Hunter